Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anitocabtagene autoleucel
- Development stage
- Phase 3
- Lead developer
- Gilead Sciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anitocabtagene autoleucel is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of relapsed or refractory multiple myeloma. It consists of autologous T cells genetically modified ex vivo to express a D-domain CAR that specifically targets B-cell maturation antigen (BCMA), using a CD8 hinge and transmembrane region fused to 4-1BB and CD3ζ intracellular signaling domains. This design aims to provide high transduction efficiency, stable CAR expression, and minimize tonic signaling. The drug has demonstrated deep responses in clinical trials, with high objective response rates in heavily pretreated multiple myeloma patients. Anitocabtagene autoleucel is being jointly developed by Arcellx and Kite (a Gilead company), with manufacturing handled by Kite for late-stage trials[1][3][5][6][7].
- Brand names
- CART-ddBCMA
- Other names
- Anti B cell maturation antigen-receptor complex T cell therapy - ArcellxAnti BCMA directed ARC T cell therapy - ArcellxBCMA-targeted cell therapy - Arcellx
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anitocabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anitocabtagene autoleucel.